恒瑞医药(600276.SH)：SHR-1905注射液获得药物临床试验批准通知书

Core Viewpoint - Heng Rui Medicine's subsidiary, Guangdong Heng Rui Medicine Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-1905 injection, which is expected to commence soon [1] Group 1: Company Developments - The SHR-1905 injection is a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), designed to block the release of inflammatory cytokines [1] - The mechanism of SHR-1905 involves inhibiting downstream inflammatory signaling pathways, ultimately improving inflammatory conditions and controlling disease progression [1]